Hussein Tawbi, MD, PHD

Trials

Studies that name Hussein Tawbi, MD, PHD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:45 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT06683755 · Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)

  M.D. Anderson Cancer Center · recruiting · Melanoma · principal investigator
• Ph2
  NCT05704647 · Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

  M.D. Anderson Cancer Center · recruiting · Melanoma (Skin) · principal investigator
• Ph1/Ph2
  NCT03131908 · Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss

  M.D. Anderson Cancer Center · completed · Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma · principal investigator
• Ph2
  NCT02816021 · Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

  M.D. Anderson Cancer Center · completed · Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma · principal investigator
• Ph2
  NCT02301039 · SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas

  Sarcoma Alliance for Research through Collaboration · completed · Soft Tissue Sarcoma, Bone Sarcoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 10:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.